DMAC vs IR · $157.4M cap vs P/E 49, rev $7.24B
DiaMedica Therapeutics Inc (DMAC) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported IR revenue for 2024-12-31 was $7.24B. Net income was $846.3M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. IR currently screens at market cap $28.27B and trailing P/E 48.8.
DMAC currently screens at market cap $157.4M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the DMAC and IR stock pages for the full models.
Not investment advice.